Mesirow Financial Investment Management Inc. Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mesirow Financial Investment Management Inc. trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.7% in the 2nd quarter, HoldingsChannel reports. The firm owned 2,624 shares of the biopharmaceutical company’s stock after selling 73 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $2,759,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. West Paces Advisors Inc. boosted its holdings in Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 23 shares during the period. Stephens Consulting LLC bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $26,000. Sachetta LLC boosted its holdings in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares during the period. Crewe Advisors LLC bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth $28,000. Finally, Lynx Investment Advisory bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $33,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on REGN shares. Wells Fargo & Company upped their target price on shares of Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Barclays increased their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $1,250.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, September 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1,109.70.

Insider Transactions at Regeneron Pharmaceuticals

In other news, EVP Marion Mccourt sold 1,137 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the transaction, the executive vice president now directly owns 12,931 shares of the company’s stock, valued at $13,540,179.41. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Marion Mccourt sold 1,137 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the transaction, the executive vice president now directly owns 12,931 shares of the company’s stock, valued at approximately $13,540,179.41. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,026 shares of company stock valued at $11,498,705. 7.48% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $1,153.08 on Tuesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20. The firm has a market capitalization of $127.05 billion, a P/E ratio of 34.06, a price-to-earnings-growth ratio of 3.97 and a beta of 0.12. The company’s 50-day moving average is $1,126.24 and its 200 day moving average is $1,027.77.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period last year, the company posted $8.79 earnings per share. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.